How Much Does Compounded Semaglutide Cost in 2026? (Honest Numbers)

What you are actually paying for

The number on a telehealth pricing page rarely tells you the whole story. The total monthly cost of compounded semaglutide breaks into four distinct components, and providers price them differently — sometimes bundled, sometimes itemized. Understanding the components is the first step to comparing two providers honestly.

The medication itself. This is the largest line item in almost every plan. Compounded semaglutide vials and pre-filled syringes come from a licensed 503A pharmacy (or in some cases a registered 503B outsourcing facility) and are priced according to the dose, the strength, and the typical month of supply. At entry-tier 0.25 mg starting doses, the medication portion is comparatively low; at maintenance 1.0-2.4 mg doses, it scales upward in most pricing models. Compounded products are not FDA-approved as finished products, which is the regulatory trade-off behind why this line item is lower than branded Wegovy or Ozempic.

The medical visit. Telehealth compounded semaglutide is dispensed against a real prescription from a licensed prescriber after a clinical evaluation. Some providers bundle this entirely into the monthly subscription; some charge a one-time intake fee of $25-$99 plus medication; some charge an ongoing membership for unlimited prescriber messaging. When comparing two providers, normalize for whether the visit is included.

Shipping. Most providers ship monthly and most include shipping in the headline price; a few charge $15-$30 per shipment separately. Cold-chain shipping (ice packs, temperature-controlled packaging) is standard for compounded GLP-1 preparations and is typically built into the price.

Monitoring, labs, and support. Some providers require baseline labs (A1C, basic metabolic panel) before the first fill. Some require periodic check-ins. Some include unlimited messaging with the clinical team; others charge for additional consultations beyond the initial visit. None of these are deal-breakers, but they show up in the realistic monthly cost when you total six months of treatment rather than month one.

Two providers can list "$199 per month" on their pricing page and have realistic total costs that differ by $50-$100 per month once labs, intake fees, and dose escalation are included. The price comparison further down lays out which providers bundle what so you can compare apples to apples.

Price ranges by provider type

Compounded semaglutide is one of three broad pricing paths for accessing GLP-1 therapy in 2026. The other two are in-clinic branded prescriptions filled through pharmacy benefit managers, and cash-pay branded prescriptions through the manufacturer direct-to-consumer (DTC) programs from Novo Nordisk (Wegovy) and Eli Lilly (Zepbound). The price ranges look very different across these paths.

The compounded telehealth path occupies the lowest end of the cash-pay range. The manufacturer DTC programs have narrowed the gap considerably from where it sat in 2023-2024, which is worth checking before defaulting to compounded — see our companion piece on whether compounded semaglutide is legal in 2026 for the regulatory framework that underlies the price difference.

The hidden fees that change real cost

The advertised monthly price is the headline. The realistic monthly cost six months in is usually higher, sometimes meaningfully so. The most common cost drivers worth knowing before signing up:

• Medical consultation or membership fees. Some providers charge a one-time intake fee of $25-$99 on top of the medication. Others charge a recurring monthly membership ($25-$50/mo) for unlimited prescriber access. Some bundle everything into a single monthly price. Read the pricing page in full before assuming the headline number is the total.
• Dose-escalation upcharges. Most compounded semaglutide protocols start at 0.25 mg weekly for the first month and escalate every four weeks toward maintenance doses of 1.0 mg, 1.7 mg, or 2.4 mg. Some providers hold a flat price across the dose ladder; others increase the monthly cost at each step. The difference between the starter tier and the maintenance tier can be $50-$150/month. Ask for the dose-tier breakdown before committing.
• Lab work. Some providers require baseline A1C, lipid panel, or basic metabolic panel before the first fill, and may require repeat labs at six or twelve months. If your provider includes labs in-network this might be $0; if you pay out of pocket through Quest or LabCorp it might be $80-$200 per round.
• Shipping. Usually bundled, but worth confirming. A few providers charge $15-$30 per shipment separately.
• Cancellation and refund terms. Some providers operate on quarterly commitments with limited refund options on opened or shipped product. Some allow monthly cancellation. Read the terms before paying for three months upfront.
• State restrictions and surcharges. Compounded GLP-1 telehealth is not legal in every state, and shipping certain product types into a few states carries surcharges or restrictions. Confirm availability in your state before paying.

When normalizing for comparison, total the first six months: intake fee + (monthly base × 6) + lab costs + any dose-escalation upcharges + shipping. That number divided by six is the real per-month cost. It is sometimes 20-40% higher than the advertised entry-tier price.

What "too cheap" looks like (the sub-$100 red flag)

The single most reliable price-related red flag in the compounded GLP-1 market is pricing below roughly $100 per month for monthly compounded semaglutide. Below-market pricing at that level typically signals one of four things, none of them good:

• Research-peptide sourcing. "Research chemical" or "not for human consumption" labeled semaglutide is sold under a legal disclaimer that excludes it from the pharmacy regulatory framework entirely. It is not compounded medication; it is unregulated chemical. The price can be very low because it bypasses pharmacy testing, prescriber oversight, and supply-chain accountability.
• Non-US API suppliers. Active pharmaceutical ingredient sourced from facilities that have never been inspected by any US regulator. Cost is lower; quality oversight is missing.
• Unregistered pharmacies. Some operators marketing as "compounding" online are not in fact licensed 503A pharmacies or registered 503B outsourcing facilities. Pricing below $100 makes legitimate compounding economically unviable in most cases.
• Unsustainable introductory promotions. Some legitimate providers occasionally run $99 first-month promotions; the realistic ongoing price is $200+ once you escalate doses and pass the introductory window. The promotional number is real for one month; the long-term cost is higher.

None of this means every below-$150 provider is illegitimate — entry tiers in the $129-$170 range do exist among licensed compounders, particularly for lowest doses or first months. The hard threshold to flag is below $100/month at maintenance dosing. If you see that, verify the pharmacy name, search the FDA 503B registry or the state pharmacy board, and request a Certificate of Analysis before paying. Our legality and verification guide walks through the 60-second verification stack.

Why prices dropped in 2024-2025 (and where they sit now)

The current 2026 pricing landscape is the product of two converging forces from 2024-2025. Worth understanding because it explains why the manufacturer DTC and compounded ranges now overlap.

Manufacturer direct-to-consumer (DTC) programs. In 2024-2025, both Novo Nordisk and Eli Lilly launched direct-to-consumer cash-pay channels — NovoCare and LillyDirect — pricing FDA-approved Wegovy and Zepbound between roughly $199 and $499 per month for self-payers, depending on dose and program. This was a major shift; before the DTC programs, cash-pay branded was $1,000+/month retail, which is why compounded telehealth at $199/month felt like a no-brainer alternative. The DTC programs narrowed the gap considerably and added the regulatory benefit of an FDA-approved finished product.

Telehealth compounded market scaling. Simultaneously, the telehealth compounded market scaled rapidly from 2022-2024 during the FDA-listed semaglutide shortage. Operators like Henry, Mochi, Hims, Ro, and a wave of smaller compounded-focused providers pushed entry pricing as low as $129/month. When the FDA resolved the semaglutide shortage in February 2025 and grace periods ended in May 2025, the broad copy-of-commercial compounding exception narrowed. Some operators exited; the remaining legitimate 503A operators with documented clinical-difference frameworks (combination products, intermediate doses, formulation changes) face higher compliance costs sometimes reflected in pricing. Average entry tiers moved up from $129-$169 in 2023 to $150-$199 in 2026.

The net result: compounded telehealth and manufacturer DTC branded now overlap in the $200-$300 range for many patients. The choice between them is less about price alone and more about whether you want an FDA-approved finished product (branded DTC) or are comfortable with the compounded regulatory framework in exchange for typically lower starting prices and more formulation flexibility (combination products, intermediate doses).

Real cost comparison of four telehealth compounded providers

Below is a neutral, factual price snapshot of six current compounded semaglutide telehealth providers as of May 2026. We have affiliate relationships with each of these providers — that relationship is disclosed in this article and does not influence the prices listed below. Headline prices are pulled from each provider's public pricing pages; you should verify directly before signing up, since prices change frequently.

All four operate inside the 503A patient-specific compounding framework with named US-licensed pharmacy partners and a real prescriber evaluation. None are FDA-approved as finished products — that phrase does not exist for any compounded preparation — but they are operating inside the regulated compounding pathway rather than outside it. For a deeper neutral comparison of provider strengths and trade-offs see our full provider comparison.

How to evaluate cost beyond the sticker price

Headline monthly price is a starting point, not the answer. The two questions that matter more for budgeting realistically:

What is the realistic treatment duration? The clinical trial design for branded semaglutide (STEP-1, PMID 33567185) ran 68 weeks and demonstrated 14.9% mean body weight reduction in the trial population at the 2.4 mg dose. The parallel tirzepatide trial SURMOUNT-1 (PMID 35658024) ran 72 weeks and demonstrated approximately 22.5% mean body weight reduction at the 15 mg dose. Real-world results vary significantly from trial outcomes. A realistic budgeting horizon is 12-18 months for a meaningful course, sometimes longer for maintenance. At $200-$300/month all-in, that is $2,400-$5,400 total. Plan the full course rather than month one.

What happens when you stop? The STEP-4 trial (PMID 33933205) showed substantial weight regain in trial participants after discontinuation of semaglutide. Many people continue some form of maintenance dosing or transition gradually rather than stopping abruptly. Whatever path you take, factoring potential maintenance cost into the realistic lifetime budget is honest planning. Lower price for a shorter course is sometimes better value than a higher price for a longer one, and sometimes the reverse — the trade-offs are real and worth understanding before you choose.

The other factors that change cost-per-outcome rather than cost-per-month: prescriber accessibility for side-effect management (changing doses early avoids buying medication you can't tolerate), formulation flexibility (intermediate doses can stretch a prescription further than the standard ladder), and cancellation/pause terms if you need to interrupt treatment for any reason. None of these show up on a pricing page, but all show up in the real cost.

Frequently asked questions

Bottom line and next steps

Compounded semaglutide in 2026 runs roughly $150-$450/month through legitimate licensed US telehealth providers, with most patients landing in the $200-$300 all-in range. The manufacturer DTC programs from Novo and Lilly now overlap the compounded range for branded Wegovy and Zepbound at $199-$499/month for self-payers, which is worth checking before defaulting to compounded — branded adds FDA finished-product approval at the cost of typically less formulation flexibility. Below roughly $100/month is a price-related red flag that the seller is likely outside the regulated pharmacy framework. The 60-second verification check (name the pharmacy, FDA 503B registry, state pharmacy board) is worth running before any provider with unusually low pricing.

Practical next steps:

• Verify each provider's current price directly from their pricing page before signing up.
• Compare side by side in our provider comparison table.
• Confirm the legality picture in Is compounded semaglutide legal in 2026?
• Read the head-to-head SkinnyRx vs Hims breakdown for the compounded-vs-branded trade-off in detail.
• Browse provider reviews for operator-by-operator detail.
• Check the FAQ for additional regulatory and clinical context.
• If you are waiting on next-generation options, the retatrutide waitlist sends notifications when FDA approval opens that pathway. Retatrutide remains investigational and NOT FDA-approved as of May 2026.

Whichever path you take, talk to a licensed physician familiar with your medical history before starting any GLP-1 medication, branded or compounded. Price is one part of the decision; clinical fit and ongoing access are the parts that determine whether the cost is worth what you get for it.

Sources & clinical references

1. [1] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. [2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024
3. [3] Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33933205
4. [4] Novo Nordisk NovoCare direct-to-consumer cash-pay pricing program (2025-2026 public pricing pages, verify current).
5. [5] Eli Lilly LillyDirect direct-to-consumer cash-pay pricing program (2025-2026 public pricing pages, verify current).
6. [6] U.S. Food & Drug Administration. FDA Drug Shortages public database — semaglutide entry resolved February 2025; tirzepatide resolved late 2024/early 2025.
7. [7] U.S. Food & Drug Administration. Registered Outsourcing Facilities (503B). Public registry, fda.gov.
8. [8] Provider pricing pages (Embody GLP1, SkinnyRx, SHED/ShedRx, GobyMeds, Eden Health) accessed May 2026. Subject to change. (Eden Health affiliate program paused 2026-05-21.)

Disclaimers

FTC Affiliate Disclosure: This article contains affiliate links to telehealth providers we have evaluated. If you sign up through these links, we may receive commission at no additional cost to you. Editorial assessment is independent — pricing reflects our research as of May 2026, not the commission paid by each provider.

Educational Disclaimer: Educational content only. Not medical advice, not financial advice. Pricing changes frequently; verify directly with each provider before signing up. Compounded products are not FDA-approved finished products. Always consult a licensed healthcare provider before starting, changing, or stopping any GLP-1 medication. Information current as of May 11, 2026.